Mattia Bellan1,2, Gabriele Pogliani1,2, Cecilia Marconi1,2, Rosalba Minisini1,2, Lisa Franzosi1,2, Federica Alciato1, Andrea Magri1,2, Gian Carlo Avanzi1,3, Mario Pirisi1,2,4, Pier Paolo Sainaghi2,4. 1. Department of Translational Medicine, Università del Piemonte Orientale UPO, via Solaroli 17, 28100 Novara, Italy. 2. Division of Internal Medicine, "AOU Maggiore della Carità", Corso Mazzini 18, 28100 Novara, Italy. 3. Emergency Medicine Department, "AOU Maggiore della Carità", Corso Mazzini 18, Novara, Italy. 4. IRCAD, Interdisciplinary Research Center of Autoimmune Diseases, via Solaroli 17, Novara, Italy.
Abstract
AIM: To evaluate serum growth arrest-specific gene 6 (Gas6) concentration as a biomarker of liver fibrosis progression. MATERIALS & METHODS: One hundred and thirteen consecutive patients affected by chronic liver disease underwent transient elastography, Gas6 measurement and, if clinically indicated, liver biopsy. RESULTS: Gas6 concentration was directly correlated to liver stiffness (r = 0.67; p < 0.0001) and was significantly higher in patients with advanced fibrosis (Ishak 4-5; p < 0.001). A plasma concentration <30 ng/ml Gas6 ruled out fibrosis with 84% sensitivity and 56% specificity, while values >42 ng/ml identified severe fibrosis with a sensitivity of 64% and a specificity of 95%; the diagnostic accuracy was comparable to that of transient elastography. CONCLUSION: Gas6 is a novel biomarker of liver fibrosis, with a potential clinical and pathophysiological relevance.
AIM: To evaluate serum growth arrest-specific gene 6 (Gas6) concentration as a biomarker of liver fibrosis progression. MATERIALS & METHODS: One hundred and thirteen consecutive patients affected by chronic liver disease underwent transient elastography, Gas6 measurement and, if clinically indicated, liver biopsy. RESULTS:Gas6 concentration was directly correlated to liver stiffness (r = 0.67; p < 0.0001) and was significantly higher in patients with advanced fibrosis (Ishak 4-5; p < 0.001). A plasma concentration <30 ng/ml Gas6 ruled out fibrosis with 84% sensitivity and 56% specificity, while values >42 ng/ml identified severe fibrosis with a sensitivity of 64% and a specificity of 95%; the diagnostic accuracy was comparable to that of transient elastography. CONCLUSION:Gas6 is a novel biomarker of liver fibrosis, with a potential clinical and pathophysiological relevance.
Authors: Milena S Espindola; David M Habiel; Rohan Narayanan; Isabelle Jones; Ana L Coelho; Lynne A Murray; Dianhua Jiang; Paul W Noble; Cory M Hogaboam Journal: Am J Respir Crit Care Med Date: 2018-06-01 Impact factor: 21.405
Authors: Livia Salmi; Francesco Gavelli; Filippo Patrucco; Marina Caputo; Gian Carlo Avanzi; Luigi Mario Castello Journal: Dis Markers Date: 2019-08-14 Impact factor: 3.434
Authors: Mattia Bellan; Micol Giulia Cittone; Stelvio Tonello; Cristina Rigamonti; Luigi Mario Castello; Francesco Gavelli; Mario Pirisi; Pier Paolo Sainaghi Journal: Int J Mol Sci Date: 2019-10-12 Impact factor: 5.923
Authors: Carlo Smirne; Cristina Rigamonti; Carla De Benedittis; Pier Paolo Sainaghi; Mattia Bellan; Michela Emma Burlone; Luigi Mario Castello; Gian Carlo Avanzi Journal: Dis Markers Date: 2019-09-08 Impact factor: 3.434
Authors: Gregor Ortmayr; Laura Brunnthaler; David Pereyra; Heidemarie Huber; Jonas Santol; Benedikt Rumpf; Sina Najarnia; Rory Smoot; Daphni Ammon; Thomas Sorz; Fabian Fritsch; Michael Schodl; Astrid Voill-Glaninger; Barbara Weitmayr; Manuela Födinger; Martin Klimpfinger; Thomas Gruenberger; Alice Assinger; Wolfgang Mikulits; Patrick Starlinger Journal: Hepatol Commun Date: 2021-12-24